To treat obesity in children, task force favors behavioral therapy over drugs like Wegovy
A national advisory organization has come down on the side of behavioral interventions, not obesity…
Category: obesity
.jpg)
A biotech’s binary bet ends badly
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)
On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us…
Opinion: What happened to obesity after Chile slew Tony the Tiger?
“In Sweeping War on Obesity, Chile slays Tony the Tiger.” So read the headline of…
What do Parkinson’s and obesity have in common?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Google’s Verily to offer GLP-1 drugs through Lightpath, its retooled chronic care app
For the second time in as many years, Google’s health tech spinout Verily is pivoting….
Bernie Sanders calls vote to subpoena Novo Nordisk U.S. head over Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders has called a vote to subpoena the…
Opinion: How faith leaders like me can help address America’s obesity epidemic
Many factors drive America’s obesity epidemic — environment, genetics, eating habits, and more. Solving the…
Opinion: Obesity drugs pose a big challenge for health care equity
Weight loss treatments have the potential to revolutionize health care in rich countries. They are…
STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study
Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of…
Study finds BMI, despite flaws, is useful estimate of body fat in children
The body mass index has long been slammed as a blunt instrument for evaluating health,…
New obesity drugs are seemingly everywhere. Black Americans feel left out
STAT teamed up with Word In Black, a network of 10 Black news publishers, to…
Black voices, Black bodies: Life in the age of Ozempic
STAT teamed up with Word In Black, a network of 10 Black news publishers, to…
Adopt These Coping Strategies so Stress Won’t Make You Sick
Stress is a natural response to challenging situations, and not all stress is harmful. However,…
Modifiable Lifestyle Habits Are Central to New A-fib Guideline
An updated atrial fibrillation (A-fib) treatment guideline redefines how the disease should be managed and…
Reversing progress, stroke rates are rising, especially in working-age adults
Stroke prevalence has been climbing over the past decade, reversing a steady decline among all…
STAT+: Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a…
Opinion: What clinical real-world data can deliver
Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs…
Listen: Live! From the STAT Breakthrough Summit West
On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West….
STAT+: Obesity drug from Roche succeeds in early test, sending company shares up
LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose…
.jpg)
STAT+: Novo to test Wegovy and other obesity drugs against alcohol-related liver disease
Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease,…
STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity…
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part…
STAT+: Eli Lilly raises earnings guidance as Zepbound sales beat expectations
Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of…
STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Newsbites: Ultraprocessed foods; juice; dancing; plant over animal foods
A Large Analysis Clarifies the Concerns About Ultraprocessed Foods Researchers on three continents collaborated to…
Are You at Risk for CKM Syndrome?
The American Heart Association (AHA) has defined a new syndrome— and strategies for addressing it—in…
Recognize Symptoms of Gynecologic Cancers
As we age, the risk of certain health issues, including gynecologic cancers, increases. Arming ourselves…
Decline in heart failure deaths has been undone, led by people under 45
Heart failure mortality rates are moving in the wrong direction, a new analysis reports, reversing…
STAT+: A spending frenzy on obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: New studies suggest GLP-1 health care costs have only begun to climb
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they’re set to…
Opinion: Moving the conversation about obesity beyond the scale
Every so often, the conversations that people in health care have become so pervasive that…
Listen: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
How does a startup compete with the likes of Eli Lilly and Novo Nordisk in…
STAT+: ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs
After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new…
STAT+: Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported positive results of its obesity drug Zepbound in obstructive sleep apnea, giving…
European regulators find no evidence of link between new obesity medicines and suicidal thoughts
LONDON — Following a nine-month investigation, European regulators said Friday they have found no evidence…
STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure
ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity,…
Opinion: STAT readers on biotech and national security, liquid-only diets before colonoscopy, and the value of weight loss drugs
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
Parkinson’s disease may be helped by GLP-1 drug, new study finds
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective…
Opinion: Medicare coverage of weight loss drugs could save the U.S. billions of dollars
The latest weight loss drugs are good. Really good. They can save lives and could…
Ozempic-like drugs linked to low, but increased risk of post-endoscopy pneumonia, study finds
Diabetes and obesity GLP-1 drugs like Ozempic, which can delay stomach emptying, have introduced a…
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it
Oprah Winfrey, true to form, is forcing America to yet again grapple with a complex…
STAT+: Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success
Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an…
STAT+: Novo Nordisk to acquire heart-disease focused Cardior Pharmaceuticals in deal worth $1.1 billion
LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in…
STAT+: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles
Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed…
Consider Minimally Invasive Options for Varicose Vein Removal
During the postmenopausal years, a red, blue, or raised rope-like vein may appear somewhere on…
STAT+: Regeneron’s plot to ‘cure’ allergies
George Yancopoulos is in touch with his teenage self. After 35 years as head scientist…
STAT+: Medicare expected to negotiate obesity drug prices soon, new analysis predicts
WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the…
STAT+: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug…
STAT+: First medicine developed to treat MASH expected to be approved soon
The Food and Drug Administration is expected to approve the first medicine developed specifically to…